Effects of propofol on malignant biological behaviors of prostate cancer DU145 cells and its mechanism

doi:10.3760/cma.j.cn371439-20220305-00088

Abstract

Abstract:

Objective To investigate the effects of propofol on malignant biological behaviors of prostate cancer DU145 cells and its possible mechanism. Methods Control group, 5-fluorouracil group （200 ng/ml）, low-dose propofol group （100 ng/ml） and high-dose propofol group （400 ng/ml） were set up. CCK-8 kit was used to measure the level of cell proliferation, Transwell method was used to measure the abilities of cell invasion and migration, flow cytometry was used to measure the level of apoptosis, and qRT-PCR and Western blotting were used to measure hepatocyte growth factor （HGF） and c-Met mRNA and protein levels. Results The survival rates of the control group, 5-fluorouracil group, low-dose propofol group and high-dose propofol group were （83.32±3.02）%, （36.29±3.54）%, （62.01±4.69）% and （40.20±5.48）% （F=8.65, P=0.006）; the apoptosis rates were （2.36±0.41）%, （12.47±0.40）%, （6.28±0.39）% and （10.24±0.37）% （F=26.73, P=0.001）. Further pairwise comparison showed that there were statistically significant differences （all P<0.05）. The numbers of penetrating membranes of the four groups were 617.45±29.86, 125.27±24.38, 407.02±32.27 and 230.74±31.59 （F=18.33, P=0.002）; the migration distances were （603.85±27.74） μm, （121.69±25.85） μm, （395.59±28.37） μm and （233.52±30.42） μm （F=27.02, P=0.001）. Further pairwise comparison showed that there were statistically significant differences （all P<0.05）. HGF mRNA expression levels of the four groups were 6.26±0.39, 1.94±0.35, 4.15±0.37 and 2.90±0.33 （F=25.31, P=0.001）; c-Met mRNA expression levels were 5.85±0.30, 2.04±0.32, 3.89±0.31 and 2.94±0.32 （F=12.12, P=0.003）; HGF protein expression levels were 1.43±0.04, 0.34±0.08, 0.86±0.06 and 0.63±0.09 （F=17.02, P=0.001）; c-Met protein expression levels were 1.63±0.14, 0.39±0.15, 0.93±0.11 and 0.64±0.17 （F=19.89, P=0.001）. Further pairwise comparison showed that there were statistically significant differences （all P<0.05）. Conclusion Propofol has obvious inhibitory effects on the malignant biological behaviors of prostate cancer DU145 cells, and the inhibitory effect of high-dose propofol is more obvious. The mechanism may be related to the inhibition of HGF and c-Met mRNA and protein expressions of DU145 cells by propofol, which inhibits the activation of HGF/c-Met pathway.

Key words: Prostate neoplasms, Propofol, c-Met, Malignant biological behaviors

Jin Ming, Zhen Shuqing, Wang Yanqiao, Shen Hongxia, Zhang Aimin, Hui Limei. Effects of propofol on malignant biological behaviors of prostate cancer DU145 cells and its mechanism[J]. Journal of International Oncology, 2022, 49(8): 453-458.

Figures/Tables 7

References 18

[1]	张小飞, 胡建鹏, 崔飞伦. 长非编码RNA在前列腺癌中的作用机制[J]. 国际肿瘤学杂志, 2021, 48(2): 117-120. DOI: 10.3760/cma.j.cn371439-20200610-00023. doi: 10.3760/cma.j.cn371439-20200610-00023
[2]	Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019[J]. Eur Urol, 2020, 77(4): 508-547. DOI: 10.1016/j.eururo.2020.01.012. doi: S0302-2838(20)30048-8 pmid: 32001144
[3]	Puccini A, Marín-Ramos NI, Bergamo F, et al. Safety and tolerabi-lity of c-MET inhibitors in cancer[J]. Drug Saf, 2019, 42(2): 211-233. DOI: 10.1007/s40264-018-0780-x. doi: 10.1007/s40264-018-0780-x
[4]	Fu R, Jiang S, Li J, et al. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression[J]. Med Oncol, 2020, 37(4): 24. DOI: 10.1007/s12032-020-01350-4. doi: 10.1007/s12032-020-01350-4
[5]	Wang Z, Dai Z, Wang B, et al. Targeting c-MET to enhance the efficacy of olaparib in prostate cancer[J]. Onco Targets Ther, 2021, 14: 4383-4389. DOI: 10.2147/OTT.S291267. doi: 10.2147/OTT.S291267
[6]	Vasileiou C, Befani C, Dimas K, et al. FGF-2 and HGF reverse abiraterone's effect οn intracellular levels of DHT in androgen-dependent and androgen independent prostate cancer cell lines[J]. J BUON, 2020, 25(2): 1141-1147.
[7]	Xu Y, Pan S, Jiang W, et al. Effects of propofol on the development of cancer in humans[J]. Cell Prolif, 2020, 53(8): e12867. DOI: 10.1111/cpr.12867. doi: 10.1111/cpr.12867
[8]	Gao X, Mi Y, Guo N, et al. The mechanism of propofol in cancer development: an updated review[J]. Asia Pac J Clin Oncol, 2020, 16(2): e3-e11. DOI: 10.1111/ajco.13301. doi: 10.1111/ajco.13301
[9]	Du XT, Wang XY, Zheng YH, et al. Propofol suppresses the growth and invasion of cervical carcinoma cells by inhibiting MIR155HG[J]. Aging (Albany NY), 2021, 13(21): 24464-24475. DOI: 10.18632/aging.203697. doi: 10.18632/aging.203697
[10]	Yu X, Shi J, Wang X, et al. Propofol affects the growth and metastasis of pancreatic cancer via ADAM8[J]. Pharmacol Rep, 2020, 72(2): 418-426. DOI: 10.1007/s43440-019-00015-y. doi: 10.1007/s43440-019-00015-y
[11]	Yang N, Liang Y, Yang P, et al. Propofol inhibits lung cancer cell viability and induces cell apoptosis by upregulating microRNA-486 expression[J]. Braz J Med Biol Res, 2017, 50(1): e5794. DOI: 10.1590/1414-431X20165794. doi: 10.1590/1414-431X20165794 pmid: 28076456
[12]	Enlund M, Berglund A, Ahlstrand R, et al. Survival after primary breast cancer surgery following propofol or sevoflurane general anesthesia-a retrospective, multicenter, database analysis of 6305 Swedish patients[J]. Acta Anaesthesiol Scand, 2020, 64(8): 1048-1054. DOI: 10.1111/aas.13644. doi: 10.1111/aas.13644 pmid: 32415980
[13]	Yang KS, Che PC, Hsieh MJ, et al. Propofol induces apoptosis and ameliorates 5‑fluorouracil resistance in OSCC cells by redu-cing the expression and secretion of amphiregulin[J]. Mol Med Rep, 2022, 25(1): 36. DOI: 10.3892/mmr.2021.12552. doi: 10.3892/mmr.2021.12552
[14]	Wang H, Zhao L, Wu J, et al. Propofol induces ROS-mediated intrinsic apoptosis and migration in triple-negative breast cancer cells[J]. Oncol Lett, 2020, 20(1): 810-816. DOI: 10.3892/ol.2020.11608. doi: 10.3892/ol.2020.11608 pmid: 32566008
[15]	Oh HN, Kwak AW, Lee MH, et al. Targeted inhibition of c-MET by podophyllotoxin promotes caspase-dependent apoptosis and suppresses cell growth in gefitinib-resistant non-small cell lung cancer cells[J]. Phytomedicine, 2021, 80: 153355. DOI: 10.1016/j.phymed.2020.153355. doi: 10.1016/j.phymed.2020.153355
[16]	Yang J, Yang L, Li S, et al. HGF/c-Met promote renal carcinoma cancer stem cells enrichment through upregulation of cir-CCDC66[J]. Technol Cancer Res Treat, 2020, 19: 15330338199 01114. DOI: 10.1177/1533033819901114. doi: 10.1177/1533033819901114
[17]	Fu J, Su X, Li Z, et al. HGF/c-MET pathway in cancer: from molecular characterization to clinical evidence[J]. Oncogene, 2021, 40(28): 4625-4651. DOI: 10.1038/s41388-021-01863-w. doi: 10.1038/s41388-021-01863-w
[18]	Qin H, Yang Y, Jiang B, et al. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met-FRA1 signaling[J]. FEBS J, 2021, 288(18): 5406-5429. DOI: 10.1111/febs.15816. doi: 10.1111/febs.15816

组别	存活率	凋亡率
对照组	83.32±3.02	2.36±0.41
5-氟尿嘧啶组（200 ng/ml）	36.29±3.54^a	12.47±0.40^a
丙泊酚低剂量组（100 ng/ml）	62.01±4.69^ab	6.28±0.39^ab
丙泊酚高剂量组（400 ng/ml）	40.20±5.48^abc	10.24±0.37^abc
F值	8.65	26.73
P值	0.006	0.001

组别	穿膜数（个）	迁移距离（μm）
对照组	617.45±29.86	603.85±27.74
5-氟尿嘧啶组（200 ng/ml）	125.27±24.38^a	121.69±25.85^a
丙泊酚低剂量组（100 ng/ml）	407.02±32.27^ab	395.59±28.37^ab
丙泊酚高剂量组（400 ng/ml）	230.74±31.59^abc	233.52±30.42^abc
F值	18.33	27.02
P值	0.002	0.001

组别	HGF mRNA	c-Met mRNA
对照组	6.26±0.39	5.85±0.30
5-氟尿嘧啶组（200 ng/ml）	1.94±0.35^a	2.04±0.32^a
丙泊酚低剂量组（100 ng/ml）	4.15±0.37^ab	3.89±0.31^ab
丙泊酚高剂量组（400 ng/ml）	2.90±0.33^abc	2.94±0.32^abc
F值	25.31	12.12
P值	0.001	0.003

组别	HGF蛋白	c-Met蛋白
对照组	1.43±0.04	1.63±0.14
5-氟尿嘧啶组（200 ng/ml）	0.34±0.08^a	0.39±0.15^a
丙泊酚低剂量组（100 ng/ml）	0.86±0.06^ab	0.93±0.11^ab
丙泊酚高剂量组（400 ng/ml）	0.63±0.09^abc	0.64±0.17^abc
F值	17.02	19.89
P值	0.001	0.001